Familial Mediterranean fever (periodic disease): history or a real problem
https://doi.org/10.14412/1996-7012-2018-3-61-69
Abstract
The review is devoted to the most common monogenic autoinflammatory disease – familial Mediterranean fever (FML) caused by MEFV gene mutation that occurs mainly in the representatives of certain ethnic groups and manifests itself as recurrent 6–72-hour attacks of pyretic fever accompanied by the phenomena of aseptic peritonitis, pleurisy, arthritis, and inflammatory rash. The disease can lead to a life-threatening complication, such as amyloidosis. FML is noted to be comorbid with a number of other inflammatory diseases: systemic vasculitis, chronic joint inflammatory diseases, and inflammatory bowel diseases. Emphasis is laid on the therapy aspects set out in the 2016 EULAR guidelines. The mainstay of treatment for FML is colchicine that prevents recurrences of the disease, minimizes the risk of amyloidosis, and should be prescribed immediately, once diagnosed. The paper deals with the definition of colchicine resistance that is observed in 5–10% of patients. Biological agents, among which interleukin-1 are most preferred, are now used to treat this category of patients. The high efficacy of these agents in patients with FML has been confirmed in randomized controlled studies.
About the Authors
E. S. Fedorov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Evgeny Stanislavovich Fedorov
34A, Kashirskoe Shosse, Moscow 115522
S. O. Salugina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999 Apr 2;97(1):133-44.
2. Fietta P. Autoinflammatory disease: the hereditary periodic fever syndromes. Acta Biomed. 2004 Aug;75(2):92-9.
3. Kuz'mina NN, Fedorov ES, Salugina SO, Movsisyan GR. Autoinflammatory diseases – modern view on the problem. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2009;47(1):63-75. (In Russ.). Doi: 10.14412/1995-4484-2009-144
4. Amaryan GG, Sarkisyan TF, Airapetyan AS. Semeinaya sredizemnomorskaya likhoradka u detei (periodicheskaya bolezn'): klinicheskie i geneticheskie aspekty. Metodicheskoe posobie [Family Mediterranean fever in children (recurrent disease): clinical and genetic aspects. Methodical manual]. Erevan; 2012.
5. Janeway TC, Mosenthal H. Unusual paroxysmal syndrome, probably allied to recurrent vomiting, with a study of nitrogen metabolism. Trans Assoc Am Physicians. 1908;23:504-18.
6. Siegal S. Benign paroxysmal peritonitis. Ann Intern Med. 1945;23:1-21.
7. Reimann HA. Periodic disease A probable syndrome including periodic fever, benign paroxysmal peritonitis, cyclic neutropenia and intermittent arthralgia. J Am Med Assoc. 1948 Jan 24;136(4):239-44.
8. Heller H, Kariv J, Sherf L, Sohar E. Familial Mediterranean fever. Harefuah. 1955;48:91-4.
9. Oganesyan LA, Avakyan VM. A number of cases of unknown infectious disease (chronic intermittent six-day fever). Sovetskaya meditsina. 1938;(16):9—12. (In Russ.).
10. Tareev EM, Nasonova VA. About so-called periodic disease. Sovetskaya meditsina. 1959;(11):23-8. (In Russ.).
11. Vinogradova OM. Periodicheskaya bolezn' [Periodic disease]. Moscow: Meditsina; 1973.
12. Aivazyan AA Periodicheskaya bolezn' [Periodic disease]. Erevan: Aiastan; 1982.
13. Arutyunyan VM, Akopyan GS. Periodicheskaya bolezn' (etiopatogeneticheskie i klinicheskie aspekty) [Periodica disease (etiopathogenetic and clinical aspects)]. Moscow: MIA; 2000.
14. Agadzhanyan V. Klinika i techenie periodicheskoi bolezni [Clinic and the course of periodic disease]. Leninsk-Kuznetskii: SO RAMN, 1998. 321 p.
15. Astvatsatryan VA, Torosyan EKh. Periodicheskaya bolezn' u detei [Periodic disease in children]. Erevan: Aiastan; 1989.
16. Tyrenko VV, Voronin SV, Belogurov AR, et al. Family Mediterranean fever in the military. Vestnik VMA. 2017;57(1):237-41. (In Russ.).
17. Revnova MO. Periodic disease in children or hereditary Mediterranean fever. Voprosy detskoi dietologii. 2017;15(3):50–2. (In Russ.). doi: 10.20953/1727-5784-2017-3-50–52.
18. The French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet. 1997 Sep;17(1):25-31.
19. The International FMF Consortium. Ancient missense mutation in a new member of the RoRet gene family are likely to cause familial Mediterrnean fever. Cell. 1997 Aug 22;90(4):797-807.
20. Padeh S, Shinar Y, Pras E, et al. Clinical and diagnostic value of genetic testing in 216 Israeli children with familial Mediterranean fever. J Rheumatol. 2003 Jan;30(1):185-90.
21. Marek-Yagel D, Berkun Y, Padeh S, et al. Clinical Disease Among Patients Heterozygous for Familial Mediterranean Fever. Arthritis Rheum. 2009 Jun;60(6): 1862-6. doi: 10.1002/art.24570.
22. Ben-Zvi I, Herskovizh C, Kukuy O, et al. Familial Mediterranean fever without MEFV mutations: a case-control study. Orphanet J Rare Dis. 2015 Mar 25;10:34. doi: 10.1186/s13023-015-0252-7.
23. Fedorov ES, Salugina SO, Kuz'mina NN. Familial Mediterranean fever in Russia: Experience of the Federal Rheumatology Center. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2017;11(2):34–40. (In Russ.). doi: 10.14412/1996-7012-2017-2-34-40
24. Park YH, Wood G, Kastner DL, Chae JJ. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol. 2016 Aug;17(8):914-21. doi: 10.1038/ni.3457. Epub 2016 Jun 6.
25. Omenetti A, Carta S, Delfino L, et al. Increased NLRP3-dependent interleukin 1β secretion in patients with familial Mediterranean fever: correlation with MEFV genotype. Ann Rheum Dis. 2014 Feb;73(2): 462-9. doi: 10.1136/annrheumdis-2012202774. Epub 2013 Mar 16.
26. Simon A, van der Meer JW. Pathogenesis of familial periodic fever syndromes or hereditary inflammatory syndromes. Am J Physiol Regul Integr Comp Physiol. 2007 Jan;292(1): R86-98. Epub 2006 Aug 24.
27. Fedorov ES, Salugina SO, Kuz'mina NN. Familial Mediterranean fever (a periodic disease): The present-day view of the problem. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(1):24-30. (In Russ.). doi: 10.14412/1996-7012-2013-2363
28. Bagci S, Toy B, Tuzun A, et al Continuity of cytokine activation in patients with familial Mediterranean fever. Clin Rheumatol. 2004 Aug;23(4):333-7. Epub 2004 May 1.
29. Ben-Chetrit E, Touitou I. Familial Mediterranean fever in the World. Arthritis Rheum. 2009 Oct 15;61(10):1447-53. doi: 10.1002/art.24458.
30. Ozen S, Frenkel J, Ruperto N, et al. The Eurofever project: towards better care for autoinflammatory disease. Eur J Pediatr. 2011 Apr;170(4):445-52. doi: 10.1007/s00431-0111411-z. Epub 2011 Mar 1.
31. Migita K, Uehara R, Nakamura Y, et al. Familial Mediterranean fever in Japan. Medicine (Baltimore). 2012 Nov;91(6):337-43. doi: 10.1097/MD.0b013e318277cf75.
32. Berdeli A, Mukctarova G, Oz A, Musayev S. MEFV gene mutation distrubution in Azerbaijan population. Pediatric Rheumatology 2015;13(Suppl 1):127. doi:10.1186/1546-0096-13-S1-P127
33. Fedorov ES, Salugina SO, Zhelyabina OV, et al. Family Mediterranean fever (periodic disease): the course of the disease in two generations of one Crimean Tatar family. Pediatriya. 2018; 97(3):83-91. (In Russ.).
34. Sarkisian T, Ajrapetian H, Belgarian, et al. Familial Mediterranean fever in Armenian population. Georgian Med News. 2008 Mar; (156):105-11.
35. http://www.statdata.ru
36. Yazar Bilge NS, Sari I, Solmaz D, et al. Comparison of early versus late onset familial Mediterranean fever. Int J Rheum Dis. 2018 Apr;21(4):880-884. doi: 10.1111/1756185X.13259. Epub 2018 Jan 5.
37. Nir-Paz R, Ben-Chetrit E, Pikarsky E, et al. Unusual presentation of familial Mediterraneanfever: role of genetic diagnosis. Ann Rheum Dis. 2000 Oct;59(10):836-8.
38. Korkmaz C, ц zdogan H, Kasapcopur ц , Yazici H. Acute phase response in familial Mediterranean fever. Ann Rheum Dis. 2002 Jan;61(1):79-81.
39. Berkun Y, Padeh S, Reichman B, et al. A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum. 2007 Dec;37(3):182-8. Epub 2007 May 23.
40. Obici L, Merlini G. Amyloidosis in autoinflammatory syndromes. Autoimmun Rev. 2012 Nov;12(1):14-7. doi: 10.1016/j.autrev.2012.07.016. Epub 2012 Aug 2.
41. Duzova A, Bakkaloglu A, Besbas N. Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol. 2003 Jul-Aug;21(4):509-14.
42. Hurwich BJ, Schwartz J, Goldfarb S. Record survival of siblingswith familial Mediterranean fever, phenotype 1 and 2. Arch Intern Med. 1970 Feb;125(2):308-11.
43. Kocak H1, Besbas N, Saatci U, Bakkaloglu A. Amyloidosis in children with familial Mediterranean fever. Turk J Pediatr. 1989 Oct-Dec;31(4):281-7.
44. Yazici H, ц zdogan H. FMF in Turkey. In: Sohar E, Gafni J, Pras M, editors. Proceedings of the 1st International Conference on Familial Mediterranean fever (Jerusalem, 1997). Tel Aviv: Freund; 1997. P. 66-71.
45. Majeed HA, Rawashdeh M, El-Shanti H, et al. Familial Mediterranean fever in children: the expanded clinical profile. Q J Med. 1990 Mar;74(275):309-18.
46. Gattorno M, editor. Familial Mediterranean fever. Springer; 2015.
47. Sohar E, Gafni J, Pras M, et al. Familial Mediterranean fever. A servey of 470 cases and review of the literature. Am J Med. 1967 Aug;43(2):227-53.
48. Sohar E, Gafni J. Tel Hashomer criteria for diagnosis of FMF. First International Conferens on FMF. London and Tel Aviv Freund Publishing Hause; 1997. 207 p.
49. Livnech A. Langevittz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997 Oct;40(10):1879-85.
50. Yalcinkaya F, Ozen S, Ozcakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009 Apr;48(4): 395-8. doi: 10.1093/rheumatology/ken509. Epub 2009 Feb 4.
51. Shohat M, Magal N, Shohat T, et al. Phenotype-genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis. Eur J Hum Genet. 1999 Apr;7(3):287-92.
52. Livneh A, Langevitz P, Shinar Y, et al. MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid. 1999 Mar;6(1):1-6.
53. Ben-Chetrit E, Backenroth R. Amyloidosis induced, end stage renal disease in patients with familial Mediterranean fever is highly associated with point mutations in the MEFV gene. Ann Rheum Dis. 2001 Feb; 60(2):146-9.
54. Cazeneuve C, Ajrapetyan H, Papin S, et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet. 2000 Nov;67(5):1136-43. Epub 2000 Oct 3.
55. Jeru I, Hayrapetyan H, Duquesnoy P, et al. Involvement of the Modifier Gene of a Human Mendelian Disorder in a Negative/ Selection Process. PLoS One. 2009 Oct 30; 4(10):e7676. doi: 10.1371/journal.pone.0007676.
56. Mukhin NA, Kozlovskaya LV, Rameev VV, et al. Risk factors for development of amyloidosis in periodic disease. Klinicheskaya farmakologiya i terapiya. 2014;23(5):40-4. (In Russ.).
57. Touitou I, Sarkisian T, Medlej-Hashim M, et al. Country as the Primary Risk Factor for Renal Amyloidosis in Familial Mediterranean Fever. Arthritis Rheum. 2007 May;56(5):1706-12.
58. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972 Dec 21;287(25):1302.
59. Kalinich T, Haffer D, Niehues T, et al. Colchicine Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and Consensus Statement. Pediatrics. 2007 Feb;119(2):e474-83. Epub 2007 Jan 22.
60. Demirkaya E, Erer B, Ozen S, BenChetrit E. Efficacy and safety of treatments in Familial Mediterranean Fever. Rheumatol Int. 2016 Mar;36(3):325-31. doi: 10.1007/s00296015-3408-9. Epub 2015 Dec 19.
61. Hentgen V, Grateu G, Kone-Paut I, et al. Evidence-based recommendation for the partial management for Familial Mediterranean Fever. Semin Arthritis Rheum. 2013 Dec;43(3): 387-91. doi: 10.1016/j.semarthrit.2013.04.011. Epub 2013 Jun 3.
62. Ozturk MA, Kanbay M, Kasapoglu B, et al. Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol. 2011 Jul-Aug;29(4 Suppl 67): S77-86. Epub 2011 Sep 27.
63. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016 Apr;75(4):644-51. doi: 10.1136/annrheumdis-2015-208690. Epub 2016 Jan 22.
64. Wand DQ, Bobfrate L, de Bari O, et al. Familial Mediterranean Fever: From Pathogenesis to Treatment. J Genet Syndr Gene Ther. 2014;5:5. doi: 10.4172/21577412.1000248
65. Batu ED, Arici ZS, Bilinger E, Ozen S. Current therapeutic opinion for managing familial Mediterranean fever. Exp Opin on Orphan Drug. 2015;3(9):1063-73.
66. Jayarakash V, Ansell G, Galler D. Colchicine overdose: the devil is in the detail. N Z Med J. 2007 Jan 26;120(1248):U2402.
67. Padeh S, Gerstein M., Berkun Y. Colchicine is a safe drug in children with familial Mediterranean fever. J Pediatr. 2012 Dec;161(6):1142-6. doi: 10.1016/j.jpeds.2012.05.047. Epub 2012 Jun 26.
68. Fradkin A, Yahav J, Zemer D, Jonas A. Colchicine-induced lactose malabsorbtion in patients with familial Mediterranean fever. Isr J Med Sci. 1995 Oct;31(10):616-20.
69. Merlin HE. Azoospermia caused by colchicines a case report. Fertil Steril. 1972 Mar;23(3):180-1.
70. Bremner WJ, Panlson CA. Colchicine and testicular function in man. N Engl J Med. 1976 Jun 17;294(25):1384-5.
71. Haimov-Kochman R, Prus D, Ben-Chetrit E. Azoospermia due to testicular amyloidosis in a patient with familial Mediterranean fever. Hum Reprod. 2001 Jun; 16(6):1218-20.
72. Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003 Oct 23;349(17):1647-55.
73. Wason S, DiGiacinto JL, Davis MW. Effects of grapefruit ad Seville orange juices on the farmacokinetic properties of colchicines in healthy subject. Clin Ther. 2012 Oct;34(10):2161-73. doi: 10.1016/j.clinthera.2012.08.007. Epub 2012 Aug 31.
74. Atasoyu EM, Evrenkaya TR, Solmazgul E. Possible colchicine rhabdomyolysis in a fluvastatine -treated patient. Ann Pharmacother. 2005 Jul-Aug;39(7-8):1368-9. Epub 2005 Jun 14.
75. Erken E, Ozer HT, Bozkurt B, et al. Early suppression of familial Mediterranean fever attacks by single medium dose methyl-prednisolone infusion. Joint Bone Spine. 2008 May; 75(3):370-2. doi: 10.1016/j.jbspin.2007.10.004. Epub 2008 Jan 18.
76. Ozen S, Kone-Paut I, Gь l A. Colchicine resistance and intolerance in familial Mediterranean fever: Definition, causes, and alternative treatments. Semin Arthritis Rheum. 2017 Aug;47(1):115-120. doi: 10.1016/j.semarthrit.2017.03.006. Epub 2017 Mar 20.
77. Akglu O, Kilik E, Kilik G, Ozgocmen S. Efficacy and safety of Biologic Treatment of Familial Mediterranean Fever. Am J Med Sci. 2013 Aug;346(2):137-41. doi: 10.1097/MAJ.0b013e318277083b.
78. Ben-Chetrit E, Aamar S. About colchicines compliance, resistance and virulence. Clin Exp Rheumatol. 2009 Mar-Apr; 27(2 Suppl 53):S1-3.
79. Karaaslan Y, Dogan J, Omma A, Can Sandika S. Compliance to colchicine treatment and disease activity in familial Mediterranean fever (FMF) patients in Middle/Black Sea Region of Turkey (in Вorum region). Pediatr Rheumatol. 2015; 13(Suppl 1):P81.
80. Van der Hilst JCh, Moutschen M, Messiaen P, et al. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics. 2016 Apr 4;10:75-80. doi: 10.2147/BTT.S102954.eCollection 2016.
81. Petropoulou AD, Robin M, Socie G, Galicier L. Transmission of familial Mediterranean fever mutation after bone marrow transplantation and successful\l treatn\ment with anakinra. Transplantation. 2010 Jul 15;90(1):102-3. doi: 10.1097/TP.0b013e3181d84cc3.
82. Ben-Zvi I, Kukuy O, Giat E, et al. Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2017 Apr;69(4):854-862. doi: 10.1002/art.39995.
83. Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012 Oct 16;157(8):533-41. doi: 10.7326/0003-4819157-8-201210160-00003.
84. De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med. 2018 May 17; 378(20):1908-1919. doi: 10.1056/NEJMoa1706314.
85. Sakalloglu O, Duzova A, Ozen S. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clin Exp Rheumatol. 2006 Jul-Aug;24(4):435-7.
86. Daysal LS, Akcil G, Goker B, et al. Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis. Arthritis Rheum. 2005 Feb 15;53(1):146-7.
87. Metyas S, Arkfeld DG, Forrester DM, et al. Infliximab treatment of familial Mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol. 2004 Jun;10(3):134-7.
88. Yuksel S, Yalcinkaya F, Acar B, et al. Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford). 2006 Oct;45(10):1307-8. Epub 2006 Jul 31.
89. Ozgocmen S, Akgul O. Anti-TNF agents in familial Mediterranean fever: reports of three cases and review of the literature. Mod Rheumatol. 2011 Dec;21(6):684-90. doi: 10.1007/s10165-011-0463-2. Epub 2011 May 13.
90. Ugurlu S, Hacioglu A, Adibnia Y, et al. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever. Orphanet J Rare Dis. 2017 May 30;12(1):105. doi: 10.1186/s13023017-0642-0.
Review
For citations:
Fedorov ES, Salugina SO. Familial Mediterranean fever (periodic disease): history or a real problem. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2018;12(3):61-69. (In Russ.) https://doi.org/10.14412/1996-7012-2018-3-61-69
Views:
4611
Email this article 